Stockscreener 앱 받기
2.36
1.26%
-0.03
시간 외 거래:
2.45
0.09
+3.81%
전일 마감가:
$2.39
열려 있는:
$2.37
하루 거래량:
119.33K
Relative Volume:
0.27
시가총액:
$7.18M
수익:
-
순이익/손실:
$2.81M
주가수익비율:
-0.1645
EPS:
-14.3497
순현금흐름:
$7.14M
1주 성능:
-7.09%
1개월 성능:
-17.48%
6개월 성능:
-34.44%
1년 성능:
-27.61%
1일 변동 폭
$2.27
$2.40
1주일 범위
$2.25
$2.6194
52주 변동 폭
$2.25
$4.29
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
명칭
Kiora Pharmaceuticals Inc
전화
858-224-9600
주소
169 SAXONY RD., ENCINITAS
KPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.36 | 7.40M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
Risk vs reward if holding onto Kiora Pharmaceuticals Inc.Deep Stock Performance and Volatility Analysis - Newser
Kiora Pharmaceuticals Inc. stock momentum explainedHistorical Volatility and Pattern Breakdown Analysis - Newser
Building trade automation scripts for Kiora Pharmaceuticals Inc.Free Real-Time Market Sentiment Tracking Tool - Newser
Is Kiora Pharmaceuticals Inc. still worth holding after the dipFree Watchlist for Smart Swing Trading - Newser
Using AI based signals to follow Kiora Pharmaceuticals Inc.Free Weekly Potential Breakout Stock List - Newser
What data driven models say about Kiora Pharmaceuticals Inc.’s futureFree Entry Plan for Oversold Reversal Stocks - Newser
Market reaction to Kiora Pharmaceuticals Inc.’s recent newsSmart Safety Strategy With Real Data Analysis - Newser
Strategies to average down on Kiora Pharmaceuticals Inc.High Accuracy Trade Setup Identification - Newser
Promising Developments and Strategic Partnerships Drive Buy Rating for Kiora Pharmaceuticals - TipRanks
Can swing trading help recover from Kiora Pharmaceuticals Inc. lossesFree Weekly Hot Picks With Buy Confidence - Newser
Why Kiora Pharmaceuticals Inc. stock attracts strong analyst attentionMonthly Long-Term Market Recap and Summary - Newser
Kiora (KPRX) Q2 Revenue Falls 100% - AOL.com
Applying sector rotation models to Kiora Pharmaceuticals Inc.Free Breakout Confirmation With Entry Tracker - Newser
Kiora Pharmaceuticals Advances Retinal Disease Pipeline - TipRanks
What machine learning models say about Kiora Pharmaceuticals Inc.Trade Ideas Based on Fundamental Metrics - Newser
Reversal indicators forming on Kiora Pharmaceuticals Inc. stockFree Day Trading Signals With High Precision - Newser
Abacus Global Management, Inc. shares rise 10.27% intraday after Kiora Pharmaceuticals reported positive Phase 2 clinical trial results for KIO-104. - AInvest
Kiora Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Statistical indicators supporting Kiora Pharmaceuticals Inc.’s strengthShort-Term Swing Opportunity Summary Sheet - Newser
Kiora pharma reports Q2 results, advances retinal disease trials - Investing.com
Kiora's Q2 Earnings Reveal Dual Phase 2 Trials Progress and $110M Asia Partnership Opportunity - Stock Titan
Is Kiora Pharmaceuticals Inc. showing signs of accumulationFree Stable Entry High Return Opportunities - Newser
What makes Kiora Pharmaceuticals Inc. stock price move sharplyReal Time Growth Signal with Smart Setup - Newser
Kiora Pharmaceuticals Inc. Stock Support and Resistance Levels You Should KnowRisk/Reward Optimization Entry Point Analysis - Newser
Kiora CEO to Reveal Latest Retinal Disease Therapeutic Developments at Major Ophthalmology Conference - Stock Titan
Applying chart zones and confluence areas to Kiora Pharmaceuticals Inc.Retirement Investment Outlook and Return Summary - Newser
What earnings revisions data tells us about Kiora Pharmaceuticals Inc.Entry Optimization Guide with Volume Analysis - Newser
Key metrics from Kiora Pharmaceuticals Inc.’s quarterly dataFree Capital Protection Trading Strategies - Newser
Applying big data sentiment scoring on Kiora Pharmaceuticals Inc.Long Hold Investment Strategy with Growth Focus - Newser
Kiora's KIO-104 receives US patent for expanded protection of inflammatory retinal diseases - Eyes On Eyecare
Visualizing Kiora Pharmaceuticals Inc. stock with heatmapsDaily Market Movers Screener with Filters - Newser
What are the latest earnings results for Kiora Pharmaceuticals Inc.Maximize gains with proven stock analysis - Jammu Links News
What catalysts could drive Kiora Pharmaceuticals Inc. stock higher in 2025Capitalize on momentum-driven investment opportunities - Jammu Links News
Intraday Charts Show Spike in Kiora Pharmaceuticals Inc. ActivityEarly Entry Picks Before News Breakout Reviewed - metal.it
Kiora Pharmaceuticals Inc (KPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):